Literature DB >> 19855998

Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.

Sohei Yamamoto1, Hitoshi Tsuda, Kosuke Miyai, Masashi Takano, Seiichi Tamai, Osamu Matsubara.   

Abstract

We have previously reported that alterations of p27(Kip1)-interacting cell-cycle proteins frequently occur during the development of endometriosis-associated ovarian clear cell adenocarcinoma (CCA; Yamamoto et al., Histopathology in press, 20). However, CCA also occurs in association with clear cell adenofibroma (CCAF). In this study, the expressions of p27(Kip1)-interacting proteins, i.e., p27(Kip1), Skp2, Cks1, cyclin A, cyclin E, and the Ki-67 labeling index (LI), were analyzed in 25 CCAFs (11 benign and 14 borderline) and 15 CCAF-associated CCAs, and compared with the expression status of each protein in the 23 previously studied endometriosis-associated CCAs. Although aberrant expression of all p27(Kip1)-interacting proteins was more frequent in the CCAF-associated CCAs than in the benign CCAFs, statistical significance was found only for Cks1 overexpression. The frequencies of p27(Kip1) downregulation and overexpression of Skp2 and cyclin A were significantly lower in CCAF-associated than in endometriosis-associated CCAs (P < 0.05, respectively). The frequencies of p27(Kip1) downregulation and Skp2 overexpression in borderline CCAFs were significantly lower than those in atypical endometriosis components in endometriosis-associated CCAs (P < 0.05, respectively). Mean Ki-67 LI increased significantly through benign (4.9%) to borderline (11.1%) CCAF and to CCAF-associated CCA (30.6%), but the latter two values were significantly lower than those in atypical endometriosis (21.4%) and endometriosis-associated CCA (46.9%; P < 0.05, respectively). These data suggest that accumulated alterations of p27(Kip1)-interacting proteins may accelerate the development of CCAs regardless of their carcinogenetic pathways, but that tumor cells in the CCAF-associated pathway appear to show slower cell-cycle progression than those in the endometriosis-associated pathway, possibly accounting for the distinct clinicopathological features of the two CCA subtypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855998     DOI: 10.1007/s00428-009-0844-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

Review 1.  Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1.

Authors:  K I Nakayama; S Hatakeyama; K Nakayama
Journal:  Biochem Biophys Res Commun       Date:  2001-04-13       Impact factor: 3.575

2.  Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage.

Authors:  X Jiang; S J Morland; A Hitchcock; E J Thomas; I G Campbell
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

3.  Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma.

Authors:  Martin Filipits; Harald Puhalla; Friedrich Wrba
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

4.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Malignant tumors arising in endometriosis.

Authors:  M Mostoufizadeh; R E Scully
Journal:  Clin Obstet Gynecol       Date:  1980-09       Impact factor: 2.190

6.  Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci.

Authors:  X Jiang; A Hitchcock; E J Bryan; R H Watson; P Englefield; E J Thomas; I G Campbell
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

7.  Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.

Authors:  K Ikeda; K Sakai; R Yamamoto; H Hareyama; N Tsumura; H Watari; M Shimizu; H Minakami; N Sakuragi
Journal:  Int J Gynecol Cancer       Date:  2003 Nov-Dec       Impact factor: 3.437

8.  Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tomoyuki Yoshikawa; Kazuya Kudoh; Tsunekazu Kita; Kenichi Furuya; Seiichi Tamai; Osamu Matsubara
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

Review 9.  Histological classification of ovarian cancer.

Authors:  Tsunehisa Kaku; Shinji Ogawa; Yoshiaki Kawano; Yoshihiro Ohishi; Hiroaki Kobayashi; Toshio Hirakawa; Hitoo Nakano
Journal:  Med Electron Microsc       Date:  2003-03

10.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Authors:  M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  3 in total

1.  CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Authors:  Hong Chang; Nan Jiang; Hua Jiang; Manujendra N Saha; Connie Qi; Wei Xu; Donna Reece
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

3.  Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Authors:  Vinayak Khattar; Jaideep V Thottassery
Journal:  J Cancer Ther       Date:  2013-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.